XTNT (Xtant Medical Holdings) Cyclically Adjusted Revenue per Share: $18.36 (As of Mar. 2026)


XTNT Xtant Medical Holdings Inc XTNT
27 GF Score
Price $0.42
GF Value $0.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Xtant Medical Holdings Cyclically Adjusted Revenue per Share?

Xtant Medical Holdings XTNT +0.60% 27 Cyclically Adjusted Revenue per Share is $18.36 as of Mar. 2026. GuruFocus rates XTNT with a GF Score™ of 27/100 and a GF Value™ of $0.62 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xtant Medical Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was $0.149. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $18.36 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Xtant Medical Holdings's average Cyclically Adjusted Revenue Growth Rate was -36.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -23.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Xtant Medical Holdings was -6.20% per year. The lowest was -23.60% per year. And the median was -14.10% per year.

As of today (2026-07-08), Xtant Medical Holdings's current stock price is $0.4195. Xtant Medical Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $18.36. Xtant Medical Holdings's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xtant Medical Holdings was 0.09. The lowest was 0.01. And the median was 0.02.


Xtant Medical Holdings  (AMEX:XTNT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xtant Medical Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.4195/18.36
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xtant Medical Holdings was 0.09. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xtant Medical Holdings Cyclically Adjusted Revenue per Share Related Terms


Xtant Medical Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xtant Medical Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings Cyclically Adjusted Revenue per Share Chart

Xtant Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.10 46.84 37.91 30.40 20.86

Xtant Medical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.72 26.95 24.63 20.86 18.36

XTNT vs POSC, LUNG, MDAI: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Xtant Medical Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Cyclically Adjusted PS Ratio falls into.


XTNT
27GF Score
Xtant Medical Holdings Inc XTNT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xtant Medical Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xtant Medical Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.149/330.2130*330.2130
=0.149

Current CPI (Mar. 2026) = 330.2130.

Xtant Medical Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 21.124 241.018 28.941
201609 22.553 241.428 30.847
201612 20.108 241.432 27.502
201703 14.663 243.801 19.860
201706 14.093 244.955 18.998
201709 12.976 246.819 17.360
201712 12.668 246.524 16.968
201803 2.380 249.554 3.149
201806 1.422 251.989 1.863
201809 1.303 252.439 1.704
201812 1.376 251.233 1.809
201903 1.261 254.202 1.638
201906 1.152 256.143 1.485
201909 1.186 256.759 1.525
201912 1.280 256.974 1.645
202003 1.122 258.115 1.435
202006 0.796 257.797 1.020
202009 1.059 260.280 1.344
202012 0.181 260.474 0.229
202103 0.154 264.877 0.192
202106 0.173 271.696 0.210
202109 0.159 274.310 0.191
202112 0.160 278.802 0.190
202203 0.149 287.504 0.171
202206 0.175 296.311 0.195
202209 0.155 296.808 0.172
202212 0.141 296.797 0.157
202303 0.165 301.836 0.181
202306 0.186 305.109 0.201
202309 0.184 307.789 0.197
202312 0.207 306.746 0.223
202403 0.214 312.332 0.226
202406 0.230 314.175 0.242
202409 0.207 315.301 0.217
202412 0.227 315.605 0.238
202503 0.230 319.799 0.237
202506 0.238 322.561 0.244
202509 0.221 324.800 0.225
202512 0.215 324.054 0.219
202603 0.149 330.213 0.149

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $18.36 mean?
Xtant Medical Holdings (XTNT) has a Cyclically Adjusted Revenue per Share of $18.36 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xtant Medical Holdings and its competitors.
Is Xtant Medical Holdings' Cyclically Adjusted Revenue per Share too high?
Xtant Medical Holdings' current Cyclically Adjusted Revenue per Share is $18.36. Overall, Xtant Medical Holdings has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Cyclically Adjusted Revenue per Share compare to POSC and LUNG?
Xtant Medical Holdings' Cyclically Adjusted Revenue per Share of $18.36 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xtant Medical Holdings and its competitors. Xtant Medical Holdings's current Cyclically Adjusted Revenue per Share is $18.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.62, compared to a current price of $0.42 — trading 32.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $18.36. Xtant Medical Holdings' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current Cyclically Adjusted Revenue per Share is $18.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (XTNT) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of $0.42 is trading 32.3% below its estimated GF Value™ of $0.62. GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.

Key valuation signals for XTNT:

  • Cyclically Adjusted Revenue per Share: $18.36
  • GF Value™: $0.62 vs. price of $0.42 (32.3% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xtant Medical Holdings Business Description

Address 664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
27GF Score

Get the complete analysis for XTNT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$0.62
GF Value